Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
Omeprazole Action Pathway
Homo sapiens
Drug Action Pathway
Omeprazole is a drug used to treat conditions such as gastroesophageal reflux disease (GERD), gastric ulcers, duodenal ulcers, erosive esophagitis, Zollinger-Ellison syndrome and stomach infections caused by Helicobacter pyloribacteria. Omeprazole is a prodrug administered orally but since it degrades rapidly at low pH, the capsule contains enteric-coated granules. After undergoing absorption in the small intestine, it passes from the blood stream into the parietal cells in the stomach, then enters the stomach lumen. It is a weak base and thus, accumulates on the outside of cell in the acidic environment.
Its main target is the H+/K+ ATPase in the parietal cells in the stomach. In parietal cells, carbonic anhydrase converts water and carbon dioxide to hydrogen bicarbonate ions and H+. The bicarbonate ions go into the blood via the chloride anion exchanger on the basolateral membrane which exchanges the hydrogen bicarbonate for Cl- ions. There is also the Na+/K+ ATPase which pumps Na+ out of the cell and K+ into the cell. The H+/K+ ATPase is located on the apical membrane and pumps the H+ from the cell into the stomach lumen and K+ from the lumen into the cell. Another transporter, the K+/Cl- symporter transports K+ and Cl- in the stomach lumen. The H+ and Cl- in the stomach lumen forms the HCl acid which, in excess, can cause disorders like ulcers.
The acidic environment in the stomach converts the prodrug omeprazole into its active form, sulfenamide. Sulfenamide then covalently binds to the cysteine residues on the alpha subunit of the H+/K+ ATPase via disulfide bridges. This binding of sulfenamide irreversibly inhibits the H+/K+ ATPase, preventing too much acid secretion in the stomach. Less acid in the stomach is favorable for symptomatic relief of disorders caused by the acid. Omeprazole is metabolized in the liver by CYP2C19 to form its main metabolite, 5-hydroxyomeprazole, which is excreted form the body in urine.
Side effects of taking omeprazole may include flatulence, abdominal pain, headache, diarrhea, nausea, vomiting, fever, upper respiratory infection
References
Omeprazole Pathway References
Fujii T, Fujita K, Takeguchi N, Sakai H: Function of K(+)-Cl(-) cotransporters in the acid secretory mechanism of gastric parietal cells. Biol Pharm Bull. 2011;34(6):810-2. doi: 10.1248/bpb.34.810.
Pubmed: 21628876
Ritter, James (2020). Rang and Dale’s Pharmacology (9th ed).
Retrieved from: https://www-clinicalkey-com.login.ezproxy.library.ualberta.ca/#!/browse/book/3-s2.0-C2016004202X
Shin JM, Kim N: Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013 Jan;19(1):25-35. doi: 10.5056/jnm.2013.19.1.25. Epub 2013 Jan 8.
Pubmed: 23350044
Shin JM, Sachs G: Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008 Dec;10(6):528-34. doi: 10.1007/s11894-008-0098-4.
Pubmed: 19006606
Shah N, Gossman W. Omeprazole. [Updated 2020 Feb 18]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK539786/
Wishart, D., Knox, C., Guo, A., Shrivastava, S., Hassanali, M., Stothard, P., . . . Woolsey, J. (2005, June). Omeprazole. Retrieved July 17, 2020, from https://www.drugbank.ca/drugs/DB00338
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
Downloads
Settings